La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

GoHealth Gestione

Gestione criteri di controllo 1/4

GoHealth's Il CEO è Vijay Kotte, nominato in Jun2022, e ha un mandato di 2.17 anni. la retribuzione annua totale è $ 5.14M, composta da 17.5% di stipendio e 82.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 5.24% delle azioni della società, per un valore di $ 8.89M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.6 anni e 2.3 anni.

Informazioni chiave

Vijay Kotte

Amministratore delegato

US$5.1m

Compenso totale

Percentuale dello stipendio del CEO	17.5%
Mandato del CEO	2.2yrs
Proprietà del CEO	5.2%
Durata media del management	1.6yrs
Durata media del Consiglio di amministrazione	2.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

GoHealth: Turning The Corner On Operating Cash Flow

May 28

GoHealth, Inc. (NASDAQ:GOCO) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 10

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Vijay Kotte rispetto agli utili di GoHealth?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$64m
Mar 31 2024	n/a	n/a	-US$67m
Dec 31 2023	US$5m	US$900k	-US$67m
Sep 30 2023	n/a	n/a	-US$127m
Jun 30 2023	n/a	n/a	-US$132m
Mar 31 2023	n/a	n/a	-US$146m
Dec 31 2022	US$10m	US$485k	-US$150m

Compensazione vs Mercato: La retribuzione totale di Vijay ($USD 5.14M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 1.52M ).

Compensazione vs guadagni: La retribuzione di Vijay è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Vijay Kotte (46 yo)

2.2yrs

Mandato

US$5,141,874

Compensazione

Mr. Vijay Kumar Kotte serves as Chief Executive Officer & Director of GoHealth, Inc. from June 06, 2022. He served as Executive Vice President, Strategy & Corporate Development and Chief Solutions Officer...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Brandon Cruz	Co-Founder & Non-Executive Co-Chairman	4.6yrs	US$500.00k	0.069% $ 126.6k
Clinton Jones	Co-Founder & Non-Executive Co-Chairman	4.6yrs	US$500.00k	0.25% $ 464.7k
Vijay Kotte	CEO & Director	2.2yrs	US$5.14m	5.24% $ 9.6m
Michael Hargis	Chief Operating Officer	1.1yrs	US$2.20m	0.48% $ 875.3k
Jason Schulz	Executive Officer	less than a year	US$1.39m	2.49% $ 4.6m
Katherine M. O'Halloran	Interim CFO & Chief Accounting Officer	1.3yrs	Nessun dato	0.035% $ 64.6k
John Shave	Vice President of Investor Relations	no data	Nessun dato	Nessun dato
Bradley Burd	Chief Legal Officer & Corporate Secretary	less than a year	Nessun dato	0.073% $ 134.2k
Stephen Moffat	Chief Marketing Officer	1.6yrs	Nessun dato	Nessun dato
Alison Moriarty	Chief People Officer	1.6yrs	Nessun dato	Nessun dato
Michael Kelley	Chief Actuary & SVP of Strategic Business Insights	1.9yrs	Nessun dato	Nessun dato

1.6yrs

Durata media

46yo

Età media

Gestione esperta: Il team dirigenziale di GOCO non è considerato esperto (durata media 1.6 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Brandon Cruz	Co-Founder & Non-Executive Co-Chairman	4.6yrs	US$500.00k	0.069% $ 126.6k
Clinton Jones	Co-Founder & Non-Executive Co-Chairman	4.6yrs	US$500.00k	0.25% $ 464.7k
Vijay Kotte	CEO & Director	2.2yrs	US$5.14m	5.24% $ 9.6m
David Fisher	Independent Director	2.3yrs	US$525.00k	0.71% $ 1.3m
Jeremy Gelber	Independent Director	4.6yrs	Nessun dato	Nessun dato
Timothy Wheatley	Director	less than a year	Nessun dato	Nessun dato
Alexander Timm	Lead Independent Director	4.6yrs	US$399.99k	0.24% $ 437.4k
Abhiraj Modi	Director	less than a year	Nessun dato	Nessun dato
Karoline Hilu	Independent Director	1.6yrs	US$355.79k	0.12% $ 229.7k

2.3yrs

Durata media

46yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di GOCO non è considerato esperto (durata media del mandato 2.3 anni), il che suggerisce un nuovo consiglio.

GoHealth Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Less than half of directors are independent

GoHealth, Inc. Announces Changes to Board of Directors

GoHealth, Inc. Announces Chief Financial Officer Changes

GoHealth, Inc. Announces Resignation of Jason Schulz as Treasurer

GoHealth, Inc., Annual General Meeting, Jun 12, 2024

GoHealth, Inc. Announces Departure of Shane Cruz, the Current Chief Strategy Officer, Whose Employment Will Terminate as of June 30, 2023

Recent updates

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

GoHealth, Inc. Provides Earnings Guidance for the Full Year 2024

New minor risk - Share price stability

GoHealth, Inc. to Report Q2, 2024 Results on Aug 08, 2024

New minor risk - Shareholder dilution

Less than half of directors are independent

GoHealth, Inc. Announces Changes to Board of Directors

New minor risk - Shareholder dilution

New minor risk - Share price stability

New minor risk - Market cap size

GoHealth, Inc. Announces Chief Financial Officer Changes

GoHealth, Inc. Announces Resignation of Jason Schulz as Treasurer

GoHealth: Turning The Corner On Operating Cash Flow

First quarter 2024 earnings released: US$0.95 loss per share (vs US$1.12 loss in 1Q 2023)

GoHealth, Inc., Annual General Meeting, Jun 12, 2024

GoHealth, Inc. to Report Q1, 2024 Results on May 09, 2024

Consensus revenue estimates fall by 18%

Robbins Geller Rudman & Dowd LLP Announces a Notice of Pendency and Proposed Settlement of Class Action in the GoHealth, Inc. Securities Litigation

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$3.40 loss per share (vs US$17.72 loss in FY 2022)

GoHealth, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Price target increased by 43% to US$20.00

GoHealth, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Group of buyers cancelled the acquisition of remaining stake in GoHealth, Inc. (NasdaqCM:GOCO).

GoHealth, Inc. Provides Earnings Guidance for the Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GoHealth, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus EPS estimates fall by 17%

GoHealth, Inc. Announces Departure of Shane Cruz, the Current Chief Strategy Officer, Whose Employment Will Terminate as of June 30, 2023

Price target increased by 31% to US$14.02

Group of buyers submitted a non-binding proposal to acquire remaining stake in GoHealth, Inc. (NasdaqCM:GOCO) for approximately $330 million.

CEO & Director recently bought US$100k worth of stock

Consensus EPS estimates upgraded to US$3.74 loss

GoHealth, Inc. (NASDAQ:GOCO) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

GoHealth, Inc. Reiterates Earnings Guidance for the Year 2023

Consensus revenue estimates decrease by 15%, EPS upgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 34%

Consensus EPS estimates fall by 37%

Gohealth, Inc. Appoints Karolina Hilu as A Class III Director

Consensus forecasts updated

GoHealth, Inc. Receives Extension Notice from Nasdaq

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new and inexperienced directors

GoHealth, Inc. to Report Q3, 2022 Results on Nov 10, 2022

GoHealth stock jumps 11% premarket on $50M private investment

GoHealth, Inc. announced delayed 10-Q filing

Price target decreased to US$1.10

GoHealth, Inc. to Report Q2, 2022 Results on Aug 15, 2022

GoHealth, Inc. Appoints Shane Cruz as Chief Strategy Officer

GoHealth, Inc. Names Jason Schulz as Chief Financial Officer

High number of new and inexperienced directors

GoHealth, Inc. Announces Executive Changes

GoHealth, Inc. Provides Revenue Guidance for the Fiscal Year Ending December 31, 2022

GoHealth, Inc., Annual General Meeting, May 25, 2022

GoHealth, Inc. Announces the Resignation of Anita Pramoda from the Board of Directors

GoHealth, Inc. announced delayed annual 10-K filing

Consensus EPS estimates fall by 68%

GoHealth, Inc. Provides Earnings Guidance for the Fourth Quarter and Full-Year Ended December 31, 2021

Price target decreased to US$4.25

GoHealth: Painful Competition, Cost Controls Are Key

Price target decreased to US$5.79

GoHealth Looks To Q4 For Submission Growth

Co-Founder recently bought US$1.9m worth of stock

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.65 loss in 3Q 2020)

Price target decreased to US$8.50